Tech Company Inital Public Offerings

Bolt Biotherapeutics IPO

On 2/5/2021, Bolt Biotherapeutics became a public company.

Transaction Overview

Announced On
Transaction Type
Proceeds Purpose
We currently expect to use our net proceeds from this offering as follows: to fund the clinical development of BDC-1001 for the treatment of four distinct groups of patients with HER2-expressing cancers through completion of our existing Phase 1/2 clinical trial; to fund completion of IND-enabling studies, chemistry, manufacturing and control, or CMC, activities and the clinical development of our CEA Boltbody ISAC program; and the remaining proceeds for PD-L1 Boltbody ISAC program, research and development activities, as well as working capital and general corporate purposes.

Company Information

Company Status
Mailing Address
640 Galveston Dr.
Redwood City, CA 94063
Email Address
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a private biotechnology company developing Boltbody Immune-stimulating Antibody Conjugates (ISAC), a new class of cancer therapeutics. These systemically-administered, tumor-targeted Boltbody therapeutics unleash the immune system to induce anti-tumor immunity.
Bolt Biotherapeutics LinkedIn Company Profile
Social Media
Bolt Biotherapeutics Company Twitter Account
Company News
Bolt Biotherapeutics News
Bolt Biotherapeutics on Facebook
Bolt Biotherapeutics on YouTube

Management Team

Email & Social
Peter Moldt
  Peter Moldt LinkedIn Profile  Peter Moldt Twitter Account  Peter Moldt News  Peter Moldt on Facebook
Chief Executive Officer
Randall Schatzman
  Randall Schatzman LinkedIn Profile  Randall Schatzman Twitter Account  Randall Schatzman News  Randall Schatzman on Facebook
Chief Financial Officer
William Quinn
  William Quinn LinkedIn Profile  William Quinn Twitter Account  William Quinn News  William Quinn on Facebook
Chief Medical Officer
Edith Perez
  Edith Perez LinkedIn Profile  Edith Perez Twitter Account  Edith Perez News  Edith Perez on Facebook
Vice President
Michael Alonso
  Michael Alonso LinkedIn Profile  Michael Alonso Twitter Account  Michael Alonso News  Michael Alonso on Facebook
Vice President
Nathan Ihle
  Nathan Ihle LinkedIn Profile  Nathan Ihle Twitter Account  Nathan Ihle News  Nathan Ihle on Facebook
Vice President
Marcin Kowanetz
  Marcin Kowanetz LinkedIn Profile  Marcin Kowanetz Twitter Account  Marcin Kowanetz News  Marcin Kowanetz on Facebook
Vice President
Brian Safina
  Brian Safina LinkedIn Profile  Brian Safina Twitter Account  Brian Safina News  Brian Safina on Facebook
VP - Bus. Development
Grant Yonehiro
  Grant Yonehiro LinkedIn Profile  Grant Yonehiro Twitter Account  Grant Yonehiro News  Grant Yonehiro on Facebook
VP - Engineering
Karla Henning
  Karla Henning LinkedIn Profile  Karla Henning Twitter Account  Karla Henning News  Karla Henning on Facebook
VP - Manufacturing
Travis Tani
  Travis Tani LinkedIn Profile  Travis Tani Twitter Account  Travis Tani News  Travis Tani on Facebook
VP - R & D
David Dornan
  David Dornan LinkedIn Profile  David Dornan Twitter Account  David Dornan News  David Dornan on Facebook



Browse more venture capital transactions:

Prev: 2/5/2021: Slync venture capital transaction
Next: 2/5/2021: Promenade venture capital transaction


Share this article


Where The Data Comes From

We report on funding rounds that are announced publicly. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary